Markets:

Overview

News

Currencies

International

Treasuries

Dyadic International, Inc. - Common Stock (NQ:DYAI)

0.9300 -0.0200 (-2.11%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Dyadic International, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

October 27, 2022

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

October 27, 2022

From Dyadic International, Inc.

Via GlobeNewswire

Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential

October 04, 2022

From Dyadic International, Inc.

Via GlobeNewswire

Recap: Dyadic International Q1 Earnings ↗

May 12, 2022

Dyadic International (NASDAQ:DYAI) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Dyadic International: Q2 Earnings Insights ↗

August 10, 2022

Dyadic International (NASDAQ:DYAI) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Preview: Dyadic International ↗

August 09, 2022

Dyadic International (NASDAQ:DYAI) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement.

Via Benzinga

Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

July 27, 2022

From Dyadic International, Inc.

Via GlobeNewswire

India Funds Affordable COVID-19 Vaccine Candidate Using Dyadic's Platform ↗

April 13, 2022

Via Benzinga

Dyadic International Earnings Perspective: Return On Capital Employed ↗

March 30, 2022

Dyadic International (NASDAQ:DYAI) brought in sales totaling $313.29 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 145.67%, resulting in a loss of $4.21...

Via Benzinga

Why Phibro Shares Are Trading Higher Today? ↗

February 10, 2022

Phibro Animal Health Corp (NASDAQ: PAHC) and Dyadic International Inc (NASDAQ: DYAI) have entered into an

Via Benzinga

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For March 29, 2022 ↗

March 29, 2022

Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.

Via Benzinga

A Preview Of Dyadic International's Earnings ↗

March 28, 2022

Dyadic International (NASDAQ:DYAI) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that Dyadic...

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

This Vaccine Stock Is Now On Janssen Pharmaceuticals, J&J, The White House's Radar ↗

January 04, 2022

Dyadic International shares were up over 6% on January 3rd. Shares are up over 35% in the last month.

Via Talk Markets

63 Biggest Movers From Friday ↗

December 20, 2021

Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

December 17, 2021

Gainers Genfit (NASDAQ:GN...

Via Benzinga

28 Stocks Moving In Friday's Mid-Day Session ↗

December 17, 2021

Gainers Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor. X4 Pharmaceuticals, Inc...

Via Benzinga

This Company has its Sights Set of Transforming the Pharmaceutical Industry With its Efficient C1 Vaccine & Drug Manufacturing Technology ↗

November 01, 2021

Photo by Testalize.me on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

Dyadic International Earnings Perspective: Return On Capital Employed ↗

September 30, 2021

Benzinga Pro data, Dyadic International (NASDAQ:DYAI) reported Q2 sales of $937.09 thousand. Earnings fell to a loss of $3.85 million, resulting in a 16.92% decrease from last...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 10, 2021

Gainers Hepion Pharmaceuticals (NASDAQ:HEPA

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021 ↗

December 17, 2021

Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ:

Via Benzinga

54 Biggest Movers From Yesterday ↗

August 26, 2021

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining over 11% on Tuesday. Regencell Bioscience recently...

Via Benzinga

Market Briefing For Thursday, Aug. 26 ↗

August 26, 2021

Underperformance by many stocks, but few that are really in trouble, is reflective of rising complacency, while technicians are frustrated at the lack of breakouts or breakdowns. That's actually fine,...

Via Talk Markets

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 25, 2021

Gainers Regencell Bioscience (NASDAQ:RGC) stock rose 100.19% to $30.63 during Wednesday's regular session. Regencell Bioscience's stock is trading at a volume of 8...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 23, 2021

Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 64.84% to $6.33 during Monday's pre-market session. The market value of their outstanding shares is at $144...

Via Benzinga

66 Biggest Movers From Yesterday ↗

August 18, 2021

Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 17, 2021

Gainers Aerpio Pharmaceuticals (NASDAQ:ARPO) stock increased by 25.72% to $2.59 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is...

Via Benzinga

48 Stocks Moving In Tuesday's Mid-Day Session ↗

August 17, 2021

Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares jumped 93% to $$8.10 after the company received a written pre-investigational new drug (pre-IND) response from the FDA...

Via Benzinga

Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal ↗

August 14, 2021

Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.